{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:34:49Z","timestamp":1787582089703,"version":"build-2736575974"},"reference-count":82,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002842","name":"Chiang Mai University","doi-asserted-by":"publisher","award":["214459"],"award-info":[{"award-number":["214459"]}],"id":[{"id":"10.13039\/501100002842","id-type":"DOI","asserted-by":"publisher"}]},{"award":["214459"],"award-info":[{"award-number":["214459"]}],"id":[{"id":"https:\/\/ror.org\/05m2fqn25","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017170","name":"Thailand Science Research and Innovation","doi-asserted-by":"publisher","award":["69A104000003"],"award-info":[{"award-number":["69A104000003"]}],"id":[{"id":"10.13039\/501100017170","id-type":"DOI","asserted-by":"publisher"}]},{"award":["69A104000003"],"award-info":[{"award-number":["69A104000003"]}],"id":[{"id":"https:\/\/ror.org\/000025p04","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet. Sci.","Veterinary Sciences"],"abstract":"<jats:p>Bovine adenovirus (BAdV)-based vectors, particularly those derived from bovine adenovirus 3 (BAdV-3), are emerging non-human adenoviral platforms for veterinary vaccine development. Adenoviral vectors are attractive for vaccination because they mediate efficient transgene expression, remain largely episomal, and induce robust innate and adaptive immune responses. However, widely used human adenoviral vectors, especially human adenovirus 5 (HAdV-5), may be compromised by pre-existing anti-vector immunity, supporting the development of rare human serotypes and non-human adenoviral alternatives. BAdV-3 is the best-characterized BAdV for recombinant vector engineering and has been used to express heterologous antigens from bovine herpesvirus-1, bovine respiratory syncytial virus, influenza virus, and Mycobacterium tuberculosis. Available evidence indicates that BAdV-based vectors can induce humoral, cellular, and mucosal immune responses and support intranasal antigen delivery. Protective efficacy has been demonstrated in selected experimental models, including mice and ferrets for influenza and tuberculosis vaccine candidates, whereas cattle challenge evidence remains more limited and is primarily represented by BHV-1 gD-expressing BAdV-3 vectors. These features make BAdV vectors relevant to bovine respiratory disease control, livestock vaccination, and One Health-oriented vaccine preparedness. Nevertheless, the platform remains at an early developmental stage. Key gaps include limited target-species efficacy data, pre-existing BAdV immunity in cattle, vector shedding, recombination risk, genetic stability, producer cell optimization, manufacturing scalability, and regulatory feasibility.<\/jats:p>","DOI":"10.3390\/vetsci13090850","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:20:43Z","timestamp":1787577643000},"page":"850","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bovine Adenovirus 3-Based Viral Vectors for Veterinary Vaccine Development: Progress, Limitations, and Future Directions"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2329-8802","authenticated-orcid":false,"given":"Nattawooti","family":"Sthitmatee","sequence":"first","affiliation":[{"name":"Laboratory of Veterinary Vaccine and Biological Products, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanya","family":"Varinrak","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Vaccine and Biological Products, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand"},{"name":"Central Laboratory for Teaching and Research, Faculty of Veterinary Medicine, Chiang Mai University, Muang, Chiang Mai 50100, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7158-108X","authenticated-orcid":false,"given":"Khwanchai","family":"Kreausukon","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Vaccine and Biological Products, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"570","DOI":"10.3181\/00379727-84-20714","article-title":"Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture","volume":"84","author":"Rowe","year":"1953","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_2","first-page":"616","article-title":"Development of adenovirus vectors for the expression of heterologous genes","volume":"6","author":"Berkner","year":"1988","journal-title":"BioTechniques"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as vaccine vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.4110\/in.2021.21.e6","article-title":"Adenovirus vectors: Excellent tools for vaccine development","volume":"21","author":"Chang","year":"2021","journal-title":"Immune Netw."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","article-title":"Characteristics of a human cell line transformed by DNA from human adenovirus type 5","volume":"36","author":"Graham","year":"1977","journal-title":"J. Gen. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1126\/science.2017680","article-title":"Adenovirus-mediated transfer of a recombinant \u03b11-antitrypsin gene to the lung epithelium in vivo","volume":"252","author":"Rosenfeld","year":"1991","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/mt.2009.130","article-title":"New insights on adenovirus as vaccine vectors","volume":"17","author":"Lasaro","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1016\/j.ymthe.2022.01.034","article-title":"Adenovirus-based vaccines\u2014A platform for pandemic preparedness against emerging viral pathogens","volume":"30","author":"Coughlan","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the severe acute respiratory syndrome coronavirus 2 pandemic","volume":"6","author":"Lorincz","year":"2021","journal-title":"npj Vaccines"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Murala, M.S., Gairola, V., Sayedahmed, E.E., and Mittal, S.K. (2025). Next-generation adenoviral vector-based vaccines for severe acute respiratory syndrome coronavirus-2. Vaccines, 13.","DOI":"10.3390\/vaccines13040406"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Kobinger","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wang, W.C., Sayedahmed, E.E., and Mittal, S.K. (2022). Significance of preexisting vector immunity and activation of innate responses for adenoviral vector-based therapy. Viruses, 14.","DOI":"10.3390\/v14122727"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.vaccine.2005.08.101","article-title":"Development of nonhuman adenoviruses as vaccine vectors","volume":"24","author":"Bangari","year":"2006","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Alhashimi, M., Elkashif, A., Sayedahmed, E.E., and Mittal, S.K. (2021). Nonhuman adenoviral vector-based platforms and their utility in designing next generation of vaccines for infectious diseases. Viruses, 13.","DOI":"10.3390\/v13081493"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1099\/0022-1317-76-1-93","article-title":"Development of a bovine adenovirus type 3-based expression vector","volume":"76","author":"Mittal","year":"1995","journal-title":"J. Gen. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1006\/viro.1998.9351","article-title":"Construction and characterization of E3-deleted bovine adenovirus type 3 expressing full-length and truncated form of bovine herpesvirus type 1 glycoprotein gD","volume":"250","author":"Zakhartchouk","year":"1998","journal-title":"Virology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9137","DOI":"10.1128\/JVI.73.11.9137-9144.1999","article-title":"Replication-defective bovine adenovirus type 3 as an expression vector","volume":"73","author":"Reddy","year":"1999","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0165-2427(00)00217-8","article-title":"The immunogenicity and efficacy of replication-defective and replication-competent bovine adenovirus-3 expressing bovine herpesvirus-1 glycoprotein gD in cattle","volume":"76","author":"Reddy","year":"2000","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12033-014-9801-x","article-title":"Recombinant bovine adenovirus-3 co-expressing bovine respiratory syncytial virus glycoprotein G and truncated glycoprotein gD of bovine herpesvirus-1 induce immune responses in cotton rats","volume":"57","author":"Brownlie","year":"2015","journal-title":"Mol. Biotechnol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/mt.2008.12","article-title":"Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus","volume":"16","author":"Singh","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.omtm.2018.07.007","article-title":"A bovine adenoviral vector-based H5N1 influenza vaccine provides enhanced immunogenicity and protection at a significantly low dose","volume":"10","author":"Sayedahmed","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100372","DOI":"10.1016\/j.xcrm.2021.100372","article-title":"A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice","volume":"2","author":"Khan","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"102594","DOI":"10.1016\/j.omtn.2025.102594","article-title":"A bovine adenoviral-vector-based universal influenza vaccine confers protection against influenza A and B viruses in mice and ferrets","volume":"36","author":"Wang","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.vaccine.2014.11.055","article-title":"Bovine adenovirus-3 as a vaccine delivery vehicle","volume":"33","author":"Ayalew","year":"2015","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sayedahmed, E.E., Gairola, V., Murala, M.S., and Mittal, S.K. (2025). Bovine adenoviral vector-based platform for vaccine development. Vaccines, 13.","DOI":"10.3390\/vaccines13050494"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ahi, Y.S., and Mittal, S.K. (2016). Components of adenovirus genome packaging. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.01503"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: The first effective in vivo gene delivery vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ymthe.2025.03.062","article-title":"Four decades of adenovirus gene transfer vectors: History and current use","volume":"33","author":"Hackett","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102027","DOI":"10.1016\/j.omtn.2023.09.004","article-title":"Construction and application of adenoviral vectors","volume":"34","author":"Zhang","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1128\/JVI.72.2.1394-1402.1998","article-title":"Nucleotide sequence, genome organization, and transcription map of bovine adenovirus type 3","volume":"72","author":"Reddy","year":"1998","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4142\/jvs.2017.18.2.217","article-title":"Bovine adenovirus type 3 virions cannot be rescued in vivo after full-length viral genome transfection in the absence of detectable polypeptide IX","volume":"18","author":"Zhang","year":"2017","journal-title":"J. Vet. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2478\/jvetres-2023-0014","article-title":"Recombinant hexon protein as a new bovine adenovirus type 3 subunit vaccine candidate","volume":"67","author":"Gundegmaa","year":"2023","journal-title":"J. Vet. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.virusres.2007.06.015","article-title":"Bovine adenovirus-3 E1A coding region contains cis-acting DNA packaging motifs","volume":"130","author":"Xing","year":"2007","journal-title":"Virus Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Khosa, S., Bravo Araya, M., Griebel, P., Arsic, N., and Tikoo, S.K. (2020). Bovine adenovirus-3 tropism for bovine leukocyte sub-populations. Viruses, 12.","DOI":"10.3390\/v12121431"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"106303","DOI":"10.1016\/j.tvjl.2025.106303","article-title":"Bovine adenovirus prevalence and its role in bovine respiratory disease complex: A systematic review and meta-analysis","volume":"310","author":"Werid","year":"2025","journal-title":"Vet. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/CDLI.11.2.351-357.2004","article-title":"Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States","volume":"11","author":"Nwanegbo","year":"2004","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Li, Q., He, S., Zou, Y., Yue, H., Tang, C., and Liu, J. (2023). Pathogenicity of a novel bovine adenovirus type 3 with a natural deletion partial fiber gene in BALB\/c mice. Front. Vet. Sci., 10.","DOI":"10.3389\/fvets.2023.1138159"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1023\/A:1008017404513","article-title":"Genetic organization and DNA sequence of early region 4 of bovine adenovirus type 3","volume":"17","author":"Lee","year":"1998","journal-title":"Virus Genes"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ayalew, L.E., Patel, A.K., Gaba, A., Islam, A., and Tikoo, S.K. (2016). Bovine adenovirus-3 pVIII suppresses cap-dependent mRNA translation possibly by interfering with the recruitment of DDX3 and translation initiation factors to the mRNA cap. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.02119"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.virol.2018.07.015","article-title":"Domains of bovine adenovirus-3 protein 22K involved in interacting with viral protein 52K and cellular importins \u03b1-5\/\u03b1-7","volume":"522","author":"Said","year":"2018","journal-title":"Virology"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zhao, X., and Tikoo, S.K. (2021). Nuclear and nucleolar localization of bovine adenovirus-3 protein V. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.579593"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0168-1702(00)00209-4","article-title":"Optimization of bovine coronavirus hemagglutinin-esterase glycoprotein expression in E3-deleted bovine adenovirus-3","volume":"70","author":"Reddy","year":"2000","journal-title":"Virus Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"RP107132","DOI":"10.7554\/eLife.107132","article-title":"RBMX2 links Mycobacterium bovis infection to epithelial\u2013mesenchymal transition and lung cancer progression","volume":"14","author":"Wang","year":"2025","journal-title":"eLife"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.vetmic.2015.08.025","article-title":"Serological detection of infection dynamics for respiratory viruses among dairy calves","volume":"180","author":"Tuncer","year":"2015","journal-title":"Vet. Microbiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/BF03547625","article-title":"A seroepidemiological survey of adenovirus activity (types 1\u20133) at two Finnish calf rearing farms","volume":"19","author":"Sihvonen","year":"1978","journal-title":"Acta Vet. Scand."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1099\/0022-1317-80-5-1263","article-title":"Mucosal immunization of calves with recombinant bovine adenovirus-3: Induction of protective immunity to bovine herpesvirus-1","volume":"80","author":"Zakhartchouk","year":"1999","journal-title":"J. Gen. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored coronavirus disease 2019 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2460\/ajvr.1988.49.01.67","article-title":"Bovine adenovirus type-3 infection in feedlot calves","volume":"49","author":"Mattson","year":"1988","journal-title":"Am. J. Vet. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/viro.2001.1176","article-title":"Mutational analysis of early region 4 of bovine adenovirus type 3","volume":"290","author":"Baxi","year":"2001","journal-title":"Virology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/viro.2002.1389","article-title":"Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines","volume":"295","author":"Tikoo","year":"2002","journal-title":"Virology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1128\/JVI.75.2.971-978.2001","article-title":"The genome of turkey herpesvirus","volume":"75","author":"Afonso","year":"2001","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Tang, N., Zhang, Y., Sadigh, Y., Moffat, K., Shen, Z., Nair, V., and Yao, Y. (2020). Generation of a triple insert live avian herpesvirus vectored vaccine using CRISPR\/Cas9-based gene editing. Vaccines, 8.","DOI":"10.3390\/vaccines8010097"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2307\/1590526","article-title":"Characterization of herpesvirus of turkeys. Replication using recombinant DNA","volume":"30","author":"Mucenski","year":"1986","journal-title":"Avian Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1080\/00071660410001667051","article-title":"Efficacy of a recombinant vaccine HVT-VP2 against Gumboro disease in the presence of maternal antibodies","volume":"44","author":"Goutebroze","year":"2003","journal-title":"Br. Poult. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1637\/9935-091511-Reg.1","article-title":"Advancement in vaccination against Newcastle disease: Recombinant HVT NDV provides high clinical protection and reduces challenge virus shedding with the absence of vaccine reactions","volume":"56","author":"Palya","year":"2012","journal-title":"Avian Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1128\/JVI.74.8.3815-3831.2000","article-title":"The genome of fowlpox virus","volume":"74","author":"Afonso","year":"2000","journal-title":"J. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.vaccine.2005.09.044","article-title":"Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials","volume":"24","author":"Coupar","year":"2006","journal-title":"Vaccine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2307\/1592516","article-title":"Failure of a recombinant fowl poxvirus vaccine containing an avian influenza hemagglutinin gene to provide consistent protection against influenza in chickens preimmunized with a fowl pox vaccine","volume":"44","author":"Swayne","year":"2000","journal-title":"Avian Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2307\/1591573","article-title":"Effect of route of administration on the efficacy of a recombinant fowlpox virus against H5N2 avian influenza","volume":"36","author":"Beard","year":"1992","journal-title":"Avian Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"11868","DOI":"10.1128\/JVI.75.23.11868-11873.2001","article-title":"Recombinant Newcastle disease virus as a vaccine vector","volume":"75","author":"Nakaya","year":"2001","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1128\/JVI.02341-07","article-title":"Expression of transgenes from Newcastle disease virus with a segmented genome","volume":"82","author":"Gao","year":"2008","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1016\/j.vaccine.2018.09.015","article-title":"Maternal antibody inhibition of recombinant Newcastle disease virus vectored vaccine in a primary or booster avian influenza vaccination program of broiler chickens","volume":"36","author":"Bertran","year":"2018","journal-title":"Vaccine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.1128\/JVI.00519-11","article-title":"Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats","volume":"85","author":"Ge","year":"2011","journal-title":"J. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6054","DOI":"10.1128\/JVI.76.12.6054-6061.2002","article-title":"The genomes of sheeppox and goatpox viruses","volume":"76","author":"Tulman","year":"2002","journal-title":"J. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1006\/viro.1994.1548","article-title":"Recombinant capripoxvirus expressing the hemagglutinin protein gene of rinderpest virus: Protection of cattle against rinderpest and lumpy skin disease viruses","volume":"204","author":"Romero","year":"1994","journal-title":"Virology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1016\/j.vaccine.2014.05.025","article-title":"Protective efficacy of a single immunization with capripoxvirus-vectored recombinant peste des petits ruminants vaccines in presence of pre-existing immunity","volume":"32","author":"Caufour","year":"2014","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Amanova, Z., Sametova, Z., Chervyakova, O., Turyskeldi, S., Kurmasheva, A., Abitayev, R., Ussembay, A., Kondibayeva, Z., Toktyrova, D., and Mazbayeva, D. (2025). BelloStage\u2122-3000 bioreactor versus conventional cultivation of recombinant capripoxvirus expressing Brucella antigens in Vero cells: A step towards the development of a new human brucellosis vaccine. Cells, 14.","DOI":"10.3390\/cells14201631"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/JVI.78.1.424-440.2004","article-title":"Complete, annotated sequence of the pseudorabies virus genome","volume":"78","author":"Klupp","year":"2004","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jviromet.2018.09.009","article-title":"Efficient transgene insertion in a pseudorabies virus vector by CRISPR\/Cas9 and marker rescue-enforced recombination","volume":"262","author":"Keil","year":"2018","journal-title":"J. Virol. Methods"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Wang, J., Song, Z., Ge, A., Guo, R., Qiao, Y., Xu, M., Wang, Z., Liu, Y., Zheng, Y., and Fan, H. (2018). Safety and immunogenicity of an attenuated Chinese pseudorabies variant by dual deletion of TK&gE genes. BMC Vet. Res., 14.","DOI":"10.1186\/s12917-018-1536-7"},{"key":"ref_75","first-page":"319","article-title":"Development of active immunity in newborn pigs with colostral antibodies by vaccination with gIII-deleted PRV","volume":"42","author":"Kit","year":"1994","journal-title":"Acta Vet. Hung."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.2460\/ajvr.1992.53.11.2164","article-title":"Effect of various vaccination procedures on shedding, latency, and reactivation of attenuated and virulent pseudorabies virus in swine","volume":"53","author":"Mengeling","year":"1992","journal-title":"Am. J. Vet. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","article-title":"Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity","volume":"77","author":"Vogels","year":"2003","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against coronavirus disease 2019","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost coronavirus disease 2019 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against severe acute respiratory syndrome coronavirus 2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults: A single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2021","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine against severe acute respiratory syndrome coronavirus 2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"}],"container-title":["Veterinary Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-7381\/13\/9\/850\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:51:30Z","timestamp":1787579490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-7381\/13\/9\/850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":82,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["vetsci13090850"],"URL":"https:\/\/doi.org\/10.3390\/vetsci13090850","relation":{},"ISSN":["2306-7381"],"issn-type":[{"value":"2306-7381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]}}}